Supernus Pharmaceuticals SUPN Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Supernus Pharmaceuticals's financing cash flow?
- Supernus Pharmaceuticals (SUPN) reported financing cash flow of $9.12M in Q1 2026.
- How has Supernus Pharmaceuticals's financing cash flow changed year-over-year?
- Supernus Pharmaceuticals's financing cash flow increased by 142.6% year-over-year, from -$21.4M to $9.12M.
- What is the long-term trend for Supernus Pharmaceuticals's financing cash flow?
- Over 3 years (2021 to 2025), Supernus Pharmaceuticals's financing cash flow has grown at a -58.8% compound annual growth rate (CAGR), from -$130.42M to $9.13M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.